

Attorney Docket No. ANDE-001/04US



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Norman L. Anderson

Examiner: Hines, Jana A.

Serial No.: 10/676,005

Art Unit: 1645

Filed: October 2, 2003

Confirmation No.: 6420

For: **HIGH SENSITIVITY QUANTITATION OF PEPTIDES BY MASS SPECTROMETRY**

U.S. Patent and Trademark Office
Customer Service Window
Mail Stop RCE
Randolph Building
401 Dulany Street
Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(c)

In accordance with the duty of disclosure set forth in 37 CFR §1.56, Applicant hereby submits the following information in conformance with 37 CFR §§1.97 and 1.98.

- Pursuant to 37 CFR §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed.
- No copies of the publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 CFR §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. ____ to which the above-identified application claims priority under 35 U.S.C. §120.
- No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 CFR §1.98.
- Publication(s) ____ listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to ____ application serial no. ____ and mailed on ____.
- Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).

05/23/2007 10676005 0000001A 501283
02 FC:1806 180.00 DA

10676005

- Enclosed is a copy of a non-English publication(s) _____. English language publication _____(copy enclosed) claims priority from this non-English publication.
- Enclosed is an explanation of non-English publication(s) ____ for which an English translation is not available.
- Enclosed is an English translation of non-English publication(s) ____ cited in the attached Form PTO/SB/08.
- Enclosed is a copy of pending patent Application Serial No. ____.

This Information Disclosure Statement is filed after the period specified in 37 CFR § 1.97(b), but before the mailing of a final action under 37 CFR §1.113; a notice of allowance under 37 CFR §1.311; or an action that otherwise closes prosecution in this application.

In accordance with 37 CFR §1.97(c):

- Fee under 37 CFR §1.17(p) in the amount of \$180.00 is hereby authorized to be charged to Deposit Account No. 50-1283; or
- Statement as specified in 37 CFR §1.97(e):
 - Each item of information contained in the Information Disclosure Statement cited herein was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
 - No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, having made a reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

Dated: May 22, 2007

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
1200 19th Street, N.W., 5th Floor
Washington, DC 20036-2421
Tel: (703) 456-8000
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:



Timothy D. Ford
Reg. No. 47,567

296693 v1/RE

Please type a plus sign (+) inside this box →



PTO/SB/08 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
Sheet	1 of 3	Application Number	10/676,005
		Filing Date	October 2, 2003
		First Named Inventor	Norman L. Anderson
		Group Art Unit	1645
		Examiner Name	Hines, Jana A.
		Attorney Docket Number	ANDE-001/04US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
74.	2002/0037532 A1	03-28-2002	Regnier et al.		
75.	2005/0064422 A1	03-24-2005	Barnidge et al.		
76.	2002/0123055 A1	09-05-2002	Estell et al.		
77.	2002/0115056 A1	08-22-2002	Goodlett		
78.	2004/0229283 A1	11-18-2004	Gygi et al.		
79.	60/334,325	11-29-2001	Lindall et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	80.	WO 00/67017	11-09-2000	Chait et al.	T ²
	81.	WO 01/86306	11-15-2001	Regnier et al.	
	82.	WO 06/128492	12-07-2006	Pratt et al.	
	83.	WO 04/013636	02-12-2004	Syngenta Participations AG	
	84.	WO 03/102220	12-11-2003	The Institute for Systems Biology	

OTHER – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	85.	BARR, J. R. et al., "Isotope Dilution-Mass Spectrometric Quantification of Specific Proteins: Model Application with Apolipoprotein A-I," Clinical Chemistry, 1996, pp. 1676-1682, Vol. 42(10).			
	86.	BERGEN, H. R. et al., "Online Single-Step Analysis of Blood Proteins: The Transferrin Story," Analytical Biochemistry, 2001, pp. 122-129, Vol. 296.			
	87.	CLARKE, N. J. et al., "Detection and Quantitation of Cellular Derived Amyloid β Peptides by Immunoprecipitation-HPLC-MS," FEBS Letters, 1998, pp. 419-423, Vol. 430.			
	88.	GRIFFIN, T. J. et al., "Toward a High-Throughput Approach to Quantitative Proteomic Analysis: Expression-Dependent Protein Identification by Mass Spectrometry," J. Am. Soc. Mass Spectrom., 2001, pp. 1238-1246, Vol. 12.			
	89.	GYGI, S. P. et al., "Proteome Analysis of Low-Abundance Proteins Using Multidimensional Chromatography and Isotope-Coded Affinity Tags," Journal of Proteome Research, 2002, pp. 47-54, Vol. 1.			
	90.	GYGI, S. P. et al., "Quantitative Analysis of Complex Protein Mixtures using Isotope-Coded Affinity Tags," Nature Biotechnology, October 1999, pp. 994-999, Vol. 17.			
	91.	GYGI, S. P. et al., "Mass Spectrometry and Proteomics," Current Opinion in Chemical Biology, 2000, pp. 489-494, Vol. 4.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
Sheet	2 of 3	Application Number	10/676,005
		Filing Date	October 2, 2003
		First Named Inventor	Norman L. Anderson
		Group Art Unit	1645
		Examiner Name	Hines, Jana A.
		Attorney Docket Number	ANDE-001/04US

OTHER – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	92.	KALKUM, M. et al., "Detection of Secreted Peptides by Using Hypothesis-Driven Multistage Mass Spectrometry," PNAS, March 4, 2003, pp. 2795-2800, Vol. 100, No. 5.		
	93.	KIERNAN, U. A. et al., "High-Throughput Analysis of Human Plasma Proteins," American Biotechnology Laboratory, March 2002, pp. 26, 28.		
	94.	KIERNAN, U. A. et al., "High-Throughput Protein Characterization Using Mass Spectrometric Immunoassay," Analytical Biochemistry, 2002, pp. 49-56, Vol. 301.		
	95.	KIERNAN, U. A. et al., "Comparative Phenotypic Analyses of Human Plasma and Urinary Retinol Binding Protein Using Mass Spectrometric Immunoassay," Biochemical and Biophysical Research Communications, 2002, pp. 401-405, Vol. 297.		
	96.	KIPPEN, A. D. et al., "Development of an Isotope Dilution Assay for Precise Determination of Insulin, C-peptide, and Proinsulin Levels in Non-Diabetic and Type II Diabetic Individuals with Comparison to Immunoassay," The Journal of Biological Chemistry, May 9, 1997, pp. 12513-12522, Vol. 272, No. 19.		
	97.	KISELAR, J. G. et al., "Antigenic Surveillance of the Influenza Virus by Mass Spectrometry," Biochemistry, 1999, pp. 14185-14191, Vol. 38.		
	98.	KISELAR, J. G. et al., "Preservation and Detection of Specific Antibody-Peptide Complexes by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry," J. Am. Soc. Mass Spectrom., 2000, pp. 746-750, Vol. 11.		
	99.	MILLER, E. J. et al., "Quantitation of Type I, III, and V Collagens in Human Tissue Samples by High-Performance Liquid Chromatography of Selected Cyanogen Bromide Peptides," Analytical Biochemistry, 1991, pp. 54-60, Vol. 196.		
	100.	REGNIER, F. E. et al., "Comparative Proteomics Based on Stable Isotope Labeling and Affinity Selection," Journal of Mass Spectrometry, 2002, pp. 133-145, Vol. 37.		
	101.	STEMMANN, O. et al., "Dual Inhibition of Sister Chromatid Separation at Metaphase," Cell, December 14, 2001, pp. 715-726, Vol. 107.		
	102.	STEWART, I. I. et al., " ¹⁸ O Labeling: A Tool for Proteomics," Rapid Communications in Mass Spectrometry, 2001, pp. 2456-2465, Vol. 15.		
	103.	TUBBS, K. A. et al., "Detection and Quantification of β -2-Microglobulin Using Mass Spectrometric Immunoassay," Analytical Biochemistry, 2001, pp. 26-35, Vol. 289.		
	104.	VAN DEN AKKER, C. R. et al., "Recycling Immobilized Antibodies," Clinical Chemistry, 1981, pp. 1954-1955, Vol. 27, No. 11.		
	105.	Supplementary European Search Report dated January 9, 2007, 4 pages.		
	106.	"Quantitative Assay of Methionine Enkephalin and β -Endorphin in Pituitary," Foreign Medical Sciences Section on Pharmacy, June 1999, pp. 173-176, Vol. 26(3).		
	107.	"New Frontline in Research of Proteome: Quantitative Proteomics," ACTA Biochimica et Biophysica Sinica, 2001, pp. 477, 479, Vol. 33(5).		
	108.	TANAKA, T. et al., "Secretory Production of Recombinant Human C-Reactive Protein in <i>Escherichia coli</i> , capable of binding with phosphorylcholine, and its characterization," Biochemical and Biophysical Research Communications, 2002, pp. 163-166, Vol. 295.		
	109.	GRONBORG, M. et al., "A Mass Spectrometry-Based Proteomic Approach for Identification of Serine/Threonine-Phosphorylated Proteins by Enrichment with Phospho-Specific Antibodies," Molecular & Cellular Proteomics, 2002, pp. 517-527, Vol. 1.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Please type a plus sign (+) inside this box ➔

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/676,005
		Filing Date	October 2, 2003
		First Named Inventor	Norman L. Anderson
		Group Art Unit	1645
		Examiner Name	Hines, Jana A.
Sheet	3 of 3	Attorney Docket Number	ANDE-001/04US

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.